Microvesicles from MM patients have also been found to express functional adenosinergic ectoenzymes that can produce ADO from ATP and NAD+,57 while treatment in vivo with daratumumab can induce the release of microvesicles expressing CD38, among other molecules such as CD39, CD73, CD203a, PD‐L1, CD55, and CD59.58 This evidence concerns the gene CD59 and Miyoshi myopathy.